As a next destination, no place would seem a larger leap than conservative, Catholic Bavaria. Except, recalls Cooper, that the University of Munich was willing to bend its rules requiring prior university teaching experience to get Pääbo. Furthermore, Pääbo won a Leibniz Prize, the most prestigious and lucrative German award for young investigators. Then, when Pääbo found out that as the holder of a chair at a German university, he would be answerable only "to the Minister of Education and to God," as Cooper puts it, Pääbo was sold.
The move to Germany in 1989 presented no language problems for Pääbo. He speaks German as well as Swedish and English, and reads Russian, French, Coptic, Latin and hieroglyphics. Although his antiauthoritarian bent does not always extend to those who work for himhe wins more arguments than he loses in the lab -he has nonetheless succeeded in fostering a laboratory 'microclimate' that is multicultural and open-minded.
Pääbo walked through another wall last year when he headed the first scientific team to read the sequence of a piece of DNA from a Neanderthal. The data supported the view that there was no mating of Neanderthals with the ancestors of modern humans and that their lineage parted from ours some 550,000 years ago.The result, dubbed by Science a "technical tour de force," was the first molecular evidence in the long-running debate over Neanderthal-human mixing.
Pääbo has become known as a paragon of caution in the study of ancient DNA. Some of his most influential papers use chemical techniques to set out the practical constraints of what can be learned from early DNA samples. One 1996 Science paper used a class of chemical changes called 'racemization' in amino acids in old samples to show that DNA older than 100,000 years was very unlikely to have been reliably preserved. This discovery has served to limit Pääbo's own work too. Curled up around a chair in stocking feet in his Munich office, Pääbo sighs and his deep voice gets even deeper: "I know it sounds depressing, but we have reached a sort of limit" in the work on Neanderthal DNA. "It would require another technical breakthrough of the order of PCR to go back any further in time." He admits that his early dreams of doing population genetics on ancient DNA samples have been "quenched" by laboratory reality.
On the heels of the publication of the Neanderthal work in Cell last July came the announcement that Pääbo would move from the University of Munich to a directorship at a new Max Planck Institute for Evolutionary Anthropology in the eastern German city of Leipzig.
Pääbo is excited about the move to Leipzig because he sees the founding of the new Institute as a unique opportunity to create a kind of 'Grand Unified Theory' of molecular and behavioural primate evolution. It is a dramatic next challenge for a career that has already brought more than its share of coups. The institute will have a projected budget of US$14.1 million and a staff of 250. And it will offer state-of-the-art primate facilities integrated with the Leipzig Zoo, an especially remarkable departure at a time when US primate facilities are being reduced in size.
Magazine R329 Svante Pääbo, putting MPI Leipzig on the map But Pääbo's own 25-person group will not grow. Instead, at the age of 42, Pääbo seems to have reached a point in his scientific development when he realizes that his future successes may result as much from his choice of collaborators as from the achievements of his own laboratory. The other directors at the new institute -a psychologist, a linguist, a molecular anthropologist, a primatologist and someone who works on the interaction of genes and culture -include some of the top primate researchers and molecular anthropologists in the world.
In the new institute, says Pääbo, "we would like to do comparative work on humans and other primates, particularly humans and chimps." Only about 2% of our DNA is different, but "what makes a chimp a chimp and a human a human," he says, "may be due more to the difference in expression of genes. No one knows."
The attempt is not without risks. The Leipzig institute is itself a kind of primate experiment, bringing several driven scientists together and asking them to do interdisciplinary research, says Pääbo. "It's a bit like putting us in an enclosure to see if all you get is alpha-male posturing or if something constructive comes out."
Steven Dickman is a writer in Cambridge, Massachusetts, USA.
Gazetteer The Wellcome Trust
What is it famous for? Being the world's biggest medical research charity. With total assets of more than £8 billion and a research budget of about £250 million a year, the Wellcome Trust outflanks even the Howard Hughes Medical Institute, its closest counterpart in the US. Beholden to no one and nothing except the wishes of its founder, Sir Henry Wellcome, the Trust essentially does exactly what it likes with its money to "support scientific research which may conduce to the improvement of the physical conditions of mankind." And as the old man's been dead for more than 60 years, that leaves plenty of scope. Quite a big fish, then? You've said it. The Trust itself is proud of its freedom and independence, claiming that it is able to fund high-risk projects that others cannot and boasting of its ability to react quickly to changing needs -for example, its decision to build the Sanger Centre near Cambridge for genomic sequencing. But some of the punters find it high-handed and arrogant.
How did it all start? On the death of Sir Henry in 1936. The share capital from his pharmaceutical company, then called the Wellcome Foundation, was vested with trustees. The trustees (now called governors) decide policy and distribute income according to the wishes laid down in his will. Sir Henry allowed for partial sale of the company in "special circumstances", and the present great wealth of the Trust was generated when the trustees took advantage of this caveat to float the company on the stock market in 1986. More shares were sold in 1992. The Wellcome Foundation was re-named Wellcome plc and then merged with Glaxo in 1995 to become Glaxo Wellcome.
Is the company still associated with the Trust? The Trust has a 4.7% stake in the pharmaceutical company, but the two are entirely independent.
So who are the all-powerful governors?
Nine "distinguished members of the scientific and financial community," says the Trust. (Note the assumption that scientists and financiers share a common community.) These distinguished persons (five of whom have knighthoods) include two financiers and seven academics -all from 'ivy-league' institutions in Oxford, Cambridge and London. The Trust is sometimes accused of being a cosy club. That may change this summer with the arrival of its new director, haematologist Mike Dexter, a definite 'outsider' from Manchester. And as to whether any women will join the governors … who knows?
Does the Trust have special interests?
Sir Henry specified that the research funded by his money was to include veterinary and tropical medicine and the history of medicine. Recently, the governors took the decision to support research on global population issues and to put more money into research in developing countries. The Trust does not normally support cancer research, because so many others do.
How do ordinary researchers get their
hands on the money? Applications for grants are competitive and assessed by peer review, with about one in three succeeding. Grants are made in three areas: biomedical research (which received £221 million in 1997); the history of medicine; and science communication (see http://www.wellcome.ac.uk). The governors take advice from expert panels in four main subject areas: infection and immunity; molecular and cell biology; neurosciences; and physiology and pharmacology. Most support goes to researchers in the UK and in the Republic of Ireland, although there is nothing to stop the Trust taking its money further afield.
So, what's science communication?
The Wellcome Trust is keen on communicating science to the 'public'. It works with the great and good of British science, such as COPUS (the Committee on the Public Understanding of Science), the Science Museum and the Association for Science Education, to make science accessible to all. It also has its own 'Science for Life' exhibition and sponsors regular public debates, and even the odd play, on topics such as genetics and mental health.
